Table 2.
Adherence to wearable devices in the cancer population.
| Country of Study | Total Study Duration (in Weeks) | Intervention Duration (in Weeks) |
Patients Recruited |
Criteria for Evaluation | Adherence (in Percentage) |
|---|---|---|---|---|---|
| The United States of America [21] | 24 | 12 | 60 | Percentage of enrolled patients who completed all assessments (10 h per day for 4 days in a week) | 95 |
| Australia [22] | 24 | 12 | 83 | Based on the given assessment completion | 94 |
| The United States of America [23] | 52 | 24 | 44 | Collection of data (days with less than 1000 steps considered as non-adherent) | 65 |
| Australia [24] | 12 | 12 | 83 | Completeness of data collection | 96 |
| The United States of America [25] | 10 | 10 | 30 | Completeness of data collection | 67 |
| Canada [26] | 24 | 12 | 45 | Completeness of data collection | 88 |
| The Netherlands [27] | 12 | 12 | 10 | Based on data collection and total wearing days |
80 |
| United Kingdom [28] | 2 | 2 | 56 | Collected data on the different days (39 patients*14 days) | 89 |
| India [29] | 7 | 7 | 44 | Users’ tolerance ability to the intensity of the program that was set using the rate of perceived exertion (RPE) | 93 |
| The United States of America [30] | 17 | 17 | 32 | Days were considered “valid” if there was any wear time recorded (5 min threshold) |
100 |
| The United States of America [31] | 10 | 10 | 10 | Completeness of data collection | 100 |
| Germany [32] | 24 | 24 | 112 | Completeness of data collection | 95 |
| Central China [33] | 8 | 8 | 143 | Completeness of data collection | 78 |
| The United States of America [34] | 8 | 8 | 45 | Completeness of data collection | 84 |
| The United States of America [35] | 20 | 8 | 34 | Completeness of data collection | 68 |
| The United States of America [36] | 43 | 43 | 44 | Completeness of data collection | 75 |
| Japan [37] | 4 | 4 | 30 | Completeness of data collection | 90 |
| France [38] | 4 | 4 | 30 | Completeness of data collection | 86 |
| Ireland [39] | 24 | 12 | 68 | Completeness of data collection | 89 |
| The United States of America [40] | 52 | 12 | 49 | Completeness of data collection | 65 |
| Switzerland [41] | 12 | 12 | 30 | Completeness of data collection and qualitative analysis of interviews |
83 |
| The United States of America [42] | 10 | 10 | 59 | Completeness of data collection | 100 |
| The United States of America [43] | 12 | 12 | 50 | Completeness of data collection | 94 |
| Australia [44] | 24 | 12 | 34 | Based on participants who completed the study criterion, which is a minimum of 1000 steps or more denoted per day. | 82 |
| Western Australia [45] | 12 | 12 | 68 | Completeness of data collection | 94 |
| The United States of America [46] | 12 | 12 | 41 | Completeness of data collection |
81 |
| South Korea [47] | 12 | 12 | 102 | Completeness of data collection | 74 |
| The United States of America [48] | 12 | 12 | 44 | Completeness of data collection | 88 |
| Taiwan [49] | 1 | 1 | 12 | Completeness of data collection | 100 |
| The United States of America [50] | 1 | 1 | 39 | Completeness of data collection | 67 |
| The United States of America [51] | 3 | 3 | 30 | Completeness of data collection | 60 |
| South Korea [52] | 52 | 52 | 555 | Completeness of data collection | 100 |
| The United States of America [53] | 3 | 3 | 41 | Based on the rate of data collected during chemotherapy | 63 |
| Taiwan [54] | 4 | 4 | 43 | Completeness of data collection | 100 |
| South Korea [55] | 12 | 12 | 37 | Equivalent to the completion of the exercise program | 84 |
| The United States of America [56] | 2 | 2 | 12 | Completeness of data collection | 92 |
| Japan [57] | 12 | 12 | 28 | Completeness of data collection | 75 |
| The United States of America [58] | 3 | 3 | 60 | In-person interviews to examine the acceptability of the device and analysis of qualitative data | 100 |